Correction to: S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102)
- 488 Downloads
Correction to: Int J Clin Oncol (2016) 21:705–712 https://doi.org/10.1007/s10147-015-0943-z
In the original publication, in Abstract, the sentence that reads as, “Oral S-1 at a dose of 80 mg/m2 was…………. drug-free interval” should read as, “Oral S-1 at a dose of 40 mg/m2 was administered twice daily for 2 weeks, followed by a 1-week drug-free interval".
In Patients and Methods, under the heading Treatment Plan, the sentence that reads as “Specifically, …………..that did not exceed 40 mg/m2 based on BSA as follows—BSA < 1.25 m2, 40 mg; BSA 1.25–1.5 m2, 50 mg twice daily; and BSA > 1.5 m2, 60 mg” should read as, “Specifically, the drug was administered orally twice daily for 14 consecutive days at a dose based on BSA as follows—BSA < 1.25 m2, 40 mg; BSA 1.25–1.5 m2, 50 mg; BSA ≥ 1.5 m2, 60 mg”.